Investigational / not FDA-approved

Thymalin

Thymic polypeptide complex — ≠ thymalfasin ≠ TB-500 ≠ Tβ4.

Editorial review:

What evidence says

Evidence snapshot

This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.

Identity lock. Thymalin is a polypeptide complex isolated from thymus (Khavinson / Morozov-line Russian thymic-peptide literature), not a single INN monomer like thymalfasin. No single PubChem parent CID is locked for the complex in this drawer — prefer that honesty over inventing a monomer badge. PubChem name collision: searching “Thymalin” can return Nonathymulin (CID 3085284) — wrong object; do not badge. Related but distinct: Thymogen (Glu-Trp / EW dipeptide, CID 100094) appears in some Thymalin composition/gene-expression papers as a component dipeptide — still not identical to the complex. Thymalin ≠ Thymosin Alpha-1 (thymalfasin) ≠ TB-500 / Ac-LKKTETQ ≠ full Tβ4 ≠ Nonathymulin. This drawer marks papers. It is not use advice.

Bottom line

Evidence is dominated by Khavinson-group hematopoiesis / immune-aging papers, older geroprotective narratives, in-vivo tumor/thymus work, and COVID-era observational or complex-therapy reports. Controlled Western-style confirmatory RCTs with clear primary endpoints are thin or absent in this PubMed set. Do not grade Thymalin papers as thymosin alpha-1 evidence, and do not turn 2002–2003 geroprotective program narratives into an anti-aging glow.

Papers

Human hematopoietic / immune differentiation and complex therapy

PMID 33237528 — Khavinson 2020

Tested: influence of Thymalin on differentiation markers of human hematopoietic stem cells and related immune-molecule expression (laboratory / translational human-cell object).

Does not show: a large confirmatory clinical RCT for infection mortality, or identity with thymalfasin.

PMID 33575961 — Khavinson 2021

Tested: results/prospects narrative for using a hematopoietic stem-cell differentiation activator (Thymalin-line framing) in complex therapy for COVID-19 patients.

Does not show: a double-blind placebo-controlled mortality RCT equivalent to TESTS for thymosin α1; observational/complex-therapy context.

PMID 36169363 — Kuznik 2022

Tested: morphological and blood-clotting indicators in severe COVID-19 patients of middle and older age in a Thymalin-associated clinical series (Russian-language clinical context).

Does not show: confirmatory randomized efficacy, or thymosin alpha-1 interchangeability.

Composition / dipeptide components (related objects — keep tagged)

PMID 37686182 — Linkova 2023

Tested: influence of KE and EW dipeptides in the composition of the Thymalin drug on gene expression and protein synthesis (component-dipeptide mechanistic work).

Does not show: that KE or EW alone equal the full Thymalin complex clinical claim, or that Thymogen (EW) is Thymalin.

PMID 11707921 — Anisimov 2000

Tested: synthetic dipeptide L-Glu-L-Trp (Thymogen-class object) on aging and spontaneous carcinogenesis in rats.

Does not show: human Thymalin RCT efficacy; dipeptide ≠ complex.

Older geroprotective / thymic-peptide narratives

PMID 12577695 — Khavinson 2002

Tested: geroprotective framing of thymalin and epithalamin (secondary clinical/experimental narrative).

Does not show: modern controlled human anti-aging proof, or Epitalon identity.

PMID 12374906 — Khavinson 2002

Tested: broad “peptides and ageing” overview including thymic/pineal peptide programs.

Does not show: a single pivotal Thymalin RCT.

PMID 14523363 — Khavinson 2003

Tested: narrative that pineal and thymus peptides prolong human life (program-level claim paper).

Does not show: a contemporary placebo-controlled longevity trial meeting modern standards.

PMID 9637345 — Morozov 1997

Tested: review of natural and synthetic thymic peptides as therapeutics for immune dysfunction (includes Thymalin-line context).

Does not show: a modern Phase 3 package for unlabeled consumer use.

Preclinical / experimental (not human grades)

PMID 29797130 — Zhukova 2018

Tested: Thymalin effects on tumor and thymus under activation-therapy conditions in vivo.

Does not show: a human oncology indication.

What is not established

A clean single-molecule PubChem identity for Thymalin. Equivalence to thymosin alpha-1 / thymalfasin, TB-500, or Tβ4. Modern Western confirmatory RCTs with hard clinical primaries. Anti-aging or COVID mortality claims from observational/complex-therapy reports. That Nonathymulin or Thymogen PubChem hits are the Thymalin complex. This drawer does not provide use advice, schedules, or sourcing.

Selected sources

33237528 33575961 36169363 37686182 11707921 12577695 12374906 14523363 9637345 29797130

What people discuss

Reported experiences

Reported topics are not established benefits.

Watch for

Risks and unknowns

Context matters. Approval of one medicine, formulation, or use does not establish approval of products sold online or other uses. This page is educational and does not provide dosing or treatment advice.

Member discussion

Compare experiences with care.

Before posting: Describe firsthand observations and uncertainty. Do not prescribe, arrange transactions, or post private health information.

◎Verified members

Join the discussion

Verified members can contribute to compound conversations.

No approved member reports yet. Thoughtful first contributions are welcome.